ClinicalTrials.gg
Status unknownNCT03798665Updated Jan 10, 2019

A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors

An observational study in Neutropenia, sponsored by Affiliated Hospital of North Sichuan Medical College. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-10.

Sponsored by Affiliated Hospital of North Sichuan Medical College · Observational

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Neutropenia with a site in China — 11 open to participants now, 12 under way, 1 of them phase 3. Neutropenia · China.

Started
2018
with 4 others
Observational
6 of 42
4 open now
Registered
22nd of 42
by date

Among the 42 studies in Neutropenia with a site in China, this one is one of 5 that started in 2018, is one of 6 observational ones, and was the 22nd registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

11 of the 42 studies in Neutropenia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neutropenia with a site in China, or all of them as a file.
02

Study summary

Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.

03

Conditions studied

  • Neutropenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

  1. Age ≥ 18 years old;
  2. Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients;
  3. The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient);
  4. Subjects volunteered to participate in this clinical trial and signed informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old;
  2. Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapy patients;
  3. The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the first chemotherapy cycle, can be any chemotherapy cycle of the patient);
  4. Subjects volunteered to participate in this clinical trial and signed .

Exclusion criteria

Exclusion Criteria:

  1. PEG-rhG-CSF was used in the current chemotherapy cycle;
  2. Have received hematopoietic stem cell transplantation or bone marrow transplantation;
  3. Other drug clinical trials are currently underway.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Interventions

  • DrugPegfilgrastim(PEG-rhG-CSF)

    From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency

06

What researchers measure

Primary outcomes

  1. Dosage of PEG-rhG-CSF in chemotherapy

    Time frame: 1 YEAR

  2. Administration time of PEG-rhG-CSF in chemotherapy

    Time frame: 1 YEAR

  3. dosing frequency of PEG-rhG-CSF in chemotherapy

    Time frame: 1 YEAR

07

Study locations

1 of 1 sites recruiting
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Jul 2019, 12 months after the start.

Of 23 observational studies under Neutropenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 190. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2019
First posted
Jan 10, 2019
StartActual
Jul 6, 2018
Primary completionEst.
Jul 6, 2019
CompletionEst.
Jul 6, 2019
Last update
Jan 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03798665
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Responsible party
DaiYuan Ma (Director of Cancer Center Affiliation: Affiliated Hospital of North Sichuan Medical College, Affiliated Hospital of North Sichuan Medical College) — Principal investigator
First posted
Jan 10, 2019
Start date
Jul 6, 2018
Primary completion
Jul 6, 2019 (estimated)
Completion
Jul 6, 2019 (estimated)
Last update
Jan 10, 2019

Study contacts

Xian Bang Tan
Contact
tbx-n9mB@126.com
13458406996

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion